JP2016501219A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501219A5 JP2016501219A5 JP2015545099A JP2015545099A JP2016501219A5 JP 2016501219 A5 JP2016501219 A5 JP 2016501219A5 JP 2015545099 A JP2015545099 A JP 2015545099A JP 2015545099 A JP2015545099 A JP 2015545099A JP 2016501219 A5 JP2016501219 A5 JP 2016501219A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- salt
- mammal
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 16
- 206010010904 Convulsion Diseases 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- VTVWCXNABHQBJT-ZDUSSCGKSA-N C[C@@H](C1=CC2=C(C=C1)NCS2)C3=NN(C=C3)C4=NC=C(C=C4)OCCO Chemical compound C[C@@H](C1=CC2=C(C=C1)NCS2)C3=NN(C=C3)C4=NC=C(C=C4)OCCO VTVWCXNABHQBJT-ZDUSSCGKSA-N 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 description 11
- 238000000034 method Methods 0.000 description 8
- 208000033001 Complex partial seizures Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 206010040703 Simple partial seizures Diseases 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 208000028326 generalized seizure Diseases 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730273P | 2012-11-27 | 2012-11-27 | |
| US61/730,273 | 2012-11-27 | ||
| PCT/US2013/070885 WO2014085153A1 (en) | 2012-11-27 | 2013-11-20 | 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}- ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501219A JP2016501219A (ja) | 2016-01-18 |
| JP2016501219A5 true JP2016501219A5 (enExample) | 2017-01-12 |
| JP6246227B2 JP6246227B2 (ja) | 2017-12-13 |
Family
ID=49753484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545099A Active JP6246227B2 (ja) | 2012-11-27 | 2013-11-20 | Ｔａｒｐ−ガンマ８依存性ａｍｐａ受容体アンタゴニストとしての６−（（ｓ）−１−｛１−［５−（２−ヒドロキシ−エトキシ）−ピリジン−２−イル］−１ｈ−ピラゾール−３−イル｝−エチル）−３ｈ−１，３−ベンゾチアゾール−２−オン |
Country Status (35)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201609719A (zh) * | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物 |
| UY36654A (es) | 2015-04-29 | 2016-10-31 | Janssen Pharmaceutica Nv | Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen |
| CN107635970B (zh) * | 2015-04-29 | 2021-03-12 | 詹森药业有限公司 | 苯并咪唑酮和苯并噻唑酮化合物以及它们作为ampa受体调节剂的用途 |
| ES2759348T3 (es) | 2015-04-29 | 2020-05-08 | Janssen Pharmaceutica Nv | Imidazopirazinas y pirazolopirimidinas y su utilización como moduladores de receptores AMPA |
| KR20170141769A (ko) | 2015-04-29 | 2017-12-26 | 얀센 파마슈티카 엔.브이. | 인돌론 화합물 및 ampa 수용체 조절제로서의 이의 용도 |
| CA3039676A1 (en) * | 2016-10-26 | 2018-05-03 | Janssen Pharmaceutica Nv | Fused bicylic pyridine compounds and their use as ampa receptor modulators |
| RU2650523C1 (ru) * | 2017-07-24 | 2018-04-16 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Производное пиридоксина для лечения эпилепсии |
| RU2703286C1 (ru) * | 2019-06-18 | 2019-10-16 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY132385A (en) * | 1995-08-31 | 2007-10-31 | Novartis Ag | 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives |
| JP2000281676A (ja) * | 1999-01-25 | 2000-10-10 | Yamanouchi Pharmaceut Co Ltd | Ａｍｐａ拮抗化合物の新規製造法 |
| CN1245386C (zh) * | 2000-06-12 | 2006-03-15 | 卫材株式会社 | 1,2－二氢吡啶化合物及其制备方法和用途 |
| US8995993B2 (en) * | 2000-10-11 | 2015-03-31 | Gogo Llc | System for managing mobile internet protocol addresses in an airborne wireless cellular network |
| AU2005316313B2 (en) * | 2004-12-17 | 2011-09-29 | Eli Lilly And Company | Novel MCH receptor antagonists |
| WO2007076161A2 (en) | 2005-12-27 | 2007-07-05 | Myriad Genetics, Inc | Compounds with therapeutic activity |
| TW200817385A (en) * | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
| CA2739559A1 (en) * | 2008-10-08 | 2010-04-15 | Pfizer Inc. | Tetrahydrofuranyl sulfonamides and pharmaceutical compositions thereof |
| AU2010204118B2 (en) * | 2009-01-12 | 2012-12-20 | Icagen, Inc. | Sulfonamide derivatives |
| AU2011261586B2 (en) * | 2010-06-01 | 2015-08-27 | Angion Biomedica Corp. | Cytochrome P450 inhibitors and uses thereof |
| WO2012137982A2 (en) * | 2011-04-05 | 2012-10-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| TW201609719A (zh) * | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物 |
-
2013
- 2013-11-17 JO JOP/2013/0331A patent/JO3225B1/ar active
- 2013-11-18 TW TW106144388A patent/TW201825484A/zh unknown
- 2013-11-18 AR ARP130104242A patent/AR093527A1/es unknown
- 2013-11-18 TW TW102141949A patent/TWI618705B/zh not_active IP Right Cessation
- 2013-11-20 EP EP13802786.7A patent/EP2925754B1/en active Active
- 2013-11-20 KR KR1020157013470A patent/KR101693133B1/ko active Active
- 2013-11-20 HR HRP20170274TT patent/HRP20170274T1/hr unknown
- 2013-11-20 US US14/084,683 patent/US8765960B2/en active Active
- 2013-11-20 EA EA201590823A patent/EA026686B1/ru not_active IP Right Cessation
- 2013-11-20 DK DK13802786.7T patent/DK2925754T3/en active
- 2013-11-20 PT PT138027867T patent/PT2925754T/pt unknown
- 2013-11-20 SI SI201330464A patent/SI2925754T1/sl unknown
- 2013-11-20 JP JP2015545099A patent/JP6246227B2/ja active Active
- 2013-11-20 UA UAA201504865A patent/UA114345C2/uk unknown
- 2013-11-20 PE PE2015000694A patent/PE20151728A1/es active IP Right Grant
- 2013-11-20 BR BR112015011200A patent/BR112015011200A2/pt not_active IP Right Cessation
- 2013-11-20 SG SG11201504164VA patent/SG11201504164VA/en unknown
- 2013-11-20 WO PCT/US2013/070885 patent/WO2014085153A1/en not_active Ceased
- 2013-11-20 HU HUE13802786A patent/HUE033447T2/en unknown
- 2013-11-20 CN CN201380061495.2A patent/CN104797578B/zh active Active
- 2013-11-20 MA MA38126A patent/MA38126B1/fr unknown
- 2013-11-20 AP AP2015008489A patent/AP2015008489A0/xx unknown
- 2013-11-20 MY MYPI2015701544A patent/MY177721A/en unknown
- 2013-11-20 PL PL13802786T patent/PL2925754T3/pl unknown
- 2013-11-20 ES ES13802786.7T patent/ES2618260T3/es active Active
- 2013-11-20 CA CA2889243A patent/CA2889243C/en active Active
- 2013-11-20 MX MX2015006697A patent/MX356478B/es active IP Right Grant
- 2013-11-20 AU AU2013352594A patent/AU2013352594B2/en active Active
-
2015
- 2015-05-14 DO DO2015000113A patent/DOP2015000113A/es unknown
- 2015-05-14 IL IL238831A patent/IL238831B/en not_active IP Right Cessation
- 2015-05-20 CR CR20150267A patent/CR20150267A/es unknown
- 2015-05-22 TN TNP2015000200A patent/TN2015000200A1/fr unknown
- 2015-05-25 PH PH12015501154A patent/PH12015501154B1/en unknown
- 2015-05-26 ZA ZA2015/03733A patent/ZA201503733B/en unknown
- 2015-05-26 CL CL2015001419A patent/CL2015001419A1/es unknown
-
2017
- 2017-02-24 CY CY20171100252T patent/CY1118657T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501219A5 (enExample) | ||
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| PH12017500493A1 (en) | Combination therapy | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EP2683382A4 (en) | DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS FABRY | |
| EA201491460A1 (ru) | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| HK1255584A1 (zh) | 使用阿坎酸及d-环丝胺酸的联合疗法 | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| FR2918282B1 (fr) | Medicament pour le traitement de la maladie de parkinson | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| MX2019004200A (es) | Terapia de combinacion. | |
| MX2014011843A (es) | Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma. | |
| EA201491048A1 (ru) | Соединения двухцепочечных рнк к casp2 и их применение | |
| RU2014150265A (ru) | Оптимальный дозовый режим антитела против nogo-a в лечении бокового амиотрофического склероза | |
| FR2918281B1 (fr) | Medicament pour le traitement de la maladie de parkinson. |